DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Varenicline Effects In Schizophrenic Smokers

Information source: Nathan Kline Institute for Psychiatric Research
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Schizophrenia; Tobocco Use Disorder; Nicotine Dependance

Intervention: Varenicline (Drug)

Phase: Phase 4

Status: Completed

Sponsored by: Nathan Kline Institute for Psychiatric Research

Official(s) and/or principal investigator(s):
Robert C Smith, MD, PhD, Principal Investigator, Affiliation: Nathan Kline insitutue fo Psychiatric Research; NYU School of Medicine

Summary

This is an open label pre-post study of the effects of clinical treatment with varenicline on 1) decreasing smoking in schizophrenic patients, 2) improving selected cognitive measures in schizophrenic patients, and 3) effects nicotinic binding to leukocytes and DNMT1 mRNA in lymphocytes. Patients are assessed on subjective and objective measures of smoking , selected cognitive measures, and special chemical measures, during baseline testing and during 8 weeks of treatment with varenicline ( 1-3 mg/day).

Clinical Details

Official title: Evaluation of Varenicline's Clinical Efficacy for Continued Smoking Abstinence When Used in the Clinical Treatment of Schizophrenic Patients Hospitalized in an Institution With a Ban on Cigarette Smoking

Study design: Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome:

self report of smoking

CO breathalyzer level

plasma nicotine and cotinine

Secondary outcome:

RBANS neuropsychological battery

Human Analogue of computer water maze task

Eligibility

Minimum age: 18 Years. Maximum age: 65 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Clinical Diagnosis of Schizophrenia or Schizoaffective Psychosis

- Recent History of Cigarette smoking

- Ages 18-65

Locations and Contacts

Manhattan Psychatirc Center, New York City, New York 10035, United States
Additional Information

Starting date: June 2007
Last updated: May 17, 2012

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017